vs
Side-by-side financial comparison of INFINITY NATURAL RESOURCES, INC. (INR) and Viridian Therapeutics, Inc.\DE (VRDN). Click either name above to swap in a different company.
INFINITY NATURAL RESOURCES, INC. is the larger business by last-quarter revenue ($115.5M vs $70.6M, roughly 1.6× Viridian Therapeutics, Inc.\DE). INFINITY NATURAL RESOURCES, INC. runs the higher net margin — 17.3% vs -49.0%, a 66.4% gap on every dollar of revenue.
Viridian Therapeutics is a clinical-stage biotechnology firm developing novel disease-modifying therapies for rare, serious autoimmune and inflammatory diseases. Its lead pipeline candidate targets thyroid eye disease, a debilitating orbital disorder, with primary market focus on North America and Europe.
INR vs VRDN — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $115.5M | $70.6M |
| Net Profit | $20.0M | $-34.6M |
| Gross Margin | — | — |
| Operating Margin | 47.0% | -56.7% |
| Net Margin | 17.3% | -49.0% |
| Revenue YoY | — | 81958.1% |
| Net Profit YoY | — | 54.9% |
| EPS (diluted) | $1.33 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $115.5M | — | ||
| Q3 25 | $78.3M | $70.6M | ||
| Q2 25 | $72.5M | — | ||
| Q1 25 | $84.2M | — |
| Q4 25 | $20.0M | — | ||
| Q3 25 | $10.4M | $-34.6M | ||
| Q2 25 | $18.0M | — | ||
| Q1 25 | $-34.6M | — |
| Q4 25 | 47.0% | — | ||
| Q3 25 | 30.5% | -56.7% | ||
| Q2 25 | 29.9% | — | ||
| Q1 25 | -104.5% | — |
| Q4 25 | 17.3% | — | ||
| Q3 25 | 13.3% | -49.0% | ||
| Q2 25 | 24.8% | — | ||
| Q1 25 | -41.1% | — |
| Q4 25 | $1.33 | — | ||
| Q3 25 | $0.65 | — | ||
| Q2 25 | $1.18 | — | ||
| Q1 25 | $-2.27 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $2.8M | $490.9M |
| Total DebtLower is stronger | $55.0K | — |
| Stockholders' EquityBook value | $307.1M | $503.0M |
| Total Assets | $1.2B | $577.1M |
| Debt / EquityLower = less leverage | 0.00× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $2.8M | — | ||
| Q3 25 | $4.6M | $490.9M | ||
| Q2 25 | $6.3M | — | ||
| Q1 25 | $4.9M | — |
| Q4 25 | $55.0K | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $123.0K | — |
| Q4 25 | $307.1M | — | ||
| Q3 25 | $288.6M | $503.0M | ||
| Q2 25 | $10.1M | — | ||
| Q1 25 | $-52.2M | — |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.1B | $577.1M | ||
| Q2 25 | $1.0B | — | ||
| Q1 25 | $953.9M | — |
| Q4 25 | 0.00× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $75.1M | $-84.6M |
| Free Cash FlowOCF − Capex | — | $-84.7M |
| FCF MarginFCF / Revenue | — | -120.1% |
| Capex IntensityCapex / Revenue | — | 0.2% |
| Cash ConversionOCF / Net Profit | 3.75× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $75.1M | — | ||
| Q3 25 | $42.1M | $-84.6M | ||
| Q2 25 | $70.4M | — | ||
| Q1 25 | $74.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | $-84.7M | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -120.1% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 0.2% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — |
| Q4 25 | 3.75× | — | ||
| Q3 25 | 4.04× | — | ||
| Q2 25 | 3.91× | — | ||
| Q1 25 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
INR
| Oil Reserves | $54.0M | 47% |
| Natural Gas Reserves | $46.8M | 41% |
| Natural Gas Liquids Reserves | $14.7M | 13% |
VRDN
Segment breakdown not available.
